Published in Cancer Weekly, March 17th, 2009
“We recently restructured CombinatoRx to focus on our core strengths; identifying novel product candidates based on synergy and selectivity,” commented Alexis Borisy, President and CEO of CombinatoRx. “While we had setbacks in 2008, we should not overlook the accomplishments which provide evidence of the fundamental value of the CombinatoRx approach”. 2008 and Recent Accomplishments Provided important clinical translational evidence for our dissociated glucocorticoid candidate, Synavive (CRx-102), with the results from COMET-1 (CRx-102...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.